WAILEA, Hawaii — Artificial intelligence for diabetic retinopathy screening can be a valuable tool, but regulatory issues still need to be addressed, according to a speaker here.
“AI is not so dissimilar from therapeutics in terms of the regulatory process and what we have to go through,” R.V. Paul Chan, MD, MSc, MBA, FACS, said at Retina 2024. “For example, if you have a new pharmacotherapy, you have to make sure it goes through all of the steps, including clinical trials, to make sure it is safe and effective. It is no different for these AI algorithms.”
To move